Prevention of Cardiovascular Events in Patients With Chronic Kidney Disease
Annals of Pharmacotherapy · 2023-12 · 57 (12) · 1425-1435
DOI: 10.1177/10600280231165774 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 07.04.2023. Verfasst von Chris M Terpening. Beteiligte Einrichtung: Department of Clinical Pharmacy, School of Pharmacy, West Virginia University, Charleston, WV, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Abstract (Originalsprache)
Objective
To examine the evidence base for lifestyle and pharmacologic interventions to reduce the risk of cardiovascular events in patients with chronic kidney disease, with an emphasis on reporting available data in distinct subtypes. Data Sources: A PubMed search (origin to February 2023) was conducted and references for selected studies were reviewed to identify additional articles. Search terms included chronic kidney disease, major adverse cardiovascular events, and heart failure hospitalization. Study Selection and Data Analysis: English language studies reporting cardiovascular outcomes data in patients with chronic kidney disease were included. Data Synthesis: Much of the data on interventions to prevent cardiovascular events in patients with chronic kidney disease are derived from observational studies or subgroup analyses of trials of broader populations. Some common recommendations, such as weight loss, may be harmful in certain patients. Others may only offer benefits in subgroups, such as those with albuminuria. Newer agents, such as SGLT2 inhibitors and finerenone, have clearer evidence of cardiovascular benefit, but these may also apply only to specific subgroups. Relevance to Patient Care and Clinical Practice: Given the prevalence of chronic kidney disease and its attendant cardiovascular risk, it is important to understand which interventions offer the greatest benefit.
Conclusions
Patients diagnosed with chronic kidney disease have markedly increased risk of cardiovascular events, including myocardial infarction, stroke, heart failure, and cardiovascular death. However, until recently, there were few cardiovascular outcome studies that targeted enrollment specifically to those patients. Certain drugs now have shown benefits to cardiovascular end points in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, School of Pharmacy, West Virginia University, Charleston, WV, USA.
ORCID-Profile: Chris M Terpening
Zitieren
APA
Terpening, C. M. (2023). Prevention of Cardiovascular Events in Patients With Chronic Kidney Disease. Annals of Pharmacotherapy, 57(12), 1425-1435. https://doi.org/10.1177/10600280231165774
Vancouver
Terpening CM. Prevention of Cardiovascular Events in Patients With Chronic Kidney Disease. Annals of Pharmacotherapy. 2023;57(12):1425-1435. doi:10.1177/10600280231165774
BibTeX
@article{Terpening2023,
author = {Terpening, Chris M},
title = {Prevention of Cardiovascular Events in Patients With Chronic Kidney Disease},
journal = {Annals of Pharmacotherapy},
year = {2023},
volume = {57},
number = {12},
pages = {1425--1435},
doi = {10.1177/10600280231165774}
}
EUVIMED